T1	intervention 22 32	exemestane
T3	total-participants 636 640	4742
T4	eligibility 82 129	postmenopausal women with primary breast cancer
T5	intervention-participants 660 664	2362
T6	control-participants 717 721	2380
T9	iv-bin-abs 901 904	183
T10	cv-bin-abs 933 936	266
T13	outcome 1163 1180	reduction in risk
T15	outcome 1234 1255	disease-free survival
T17	outcome 1352 1368	Overall survival
T18	iv-bin-abs 1425 1427	93
T19	cv-bin-abs 1473 1476	106
T20	outcome 1547 1574	Contralateral breast cancer
T21	cv-bin-abs 1587 1589	20
T22	iv-bin-abs 1626 1627	9
T11	outcome-Measure 606 627	disease-free survival
T2	control 745 754	tamoxifen
T7	outcome 1428 1434	deaths
T12	iv-bin-percent 1152 1162	32 percent
T14	iv-bin-percent 1259 1270	4.7 percent
T8	outcome 815 845	local or metastatic recurrence
T16	outcome 847 874	contralateral breast cancer
T23	outcome 879 884	death
T24	outcome 1501 1521	Severe toxic effects
